Shiyao Holdings Group Co., Ltd

1、 Enterprise Overview: Shiyao Holding Group Co., Ltd. is a national level innovative enterprise that integrates innovative drug research and development, production, and sales. The total assets of the entire group are 49 billion yuan, and there are 27000 employees. Listed companies in Hong Kong (01093. HK) have joined the club with a market value of 100 billion yuan. They are part of the Hang Seng Index and the first pharmaceutical stock in the 50 years since the Hang Seng Index was compiled. On March 22, 2019, its subsidiary Xinnuowei (300765. SZ) successfully listed on the ChiNext, marking a new era of "red chip+A" financing pattern for Shiyao Group. Since its establishment, Shiyao Group has been continuously exploring and innovating with the strong support of the provincial and municipal governments and various sectors of society, striving to achieve sustained, healthy, and rapid development. At present, there are more than 10 drug production bases in provinces and cities such as Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, and Tianjin, with product sales covering more than 100 countries and regions worldwide, and 34 varieties with single variety sales exceeding 100 million yuan. In 2019, the entire group achieved sales revenue of 36.456 billion yuan and paid various taxes of 3.04 billion yuan, making outstanding contributions to promoting the development of China's pharmaceutical industry and regional economic construction. Adhering to the corporate mission of "making good medicine, serving China, and serving the people of the world", Shiyao Group continues to research and develop innovative products and enhance production capacity. Currently, the group has over a thousand production documents and a wide range of product combinations, which can meet the health needs of different disease groups. At present, Shiyao Group has established an integrated research and development system both domestically and internationally. It has research and development and clinical centers in Beijing, Shanghai, and Shijiazhuang, as well as clinical offices in 8 cities such as Wuhan and Shenyang. It has research and development centers and clinical centers in 4 places such as California, Texas, and New Jersey in the United States, with an annual investment of over 2 billion yuan in research and development expenses. The entire group has 1800 R&D personnel, including over 200 doctoral talents and high-end overseas returnees. At present, the group has about 300 innovative drug product projects, including more than 50 new target macromolecular innovative drugs, more than 40 small molecule innovative drugs, and more than 20 new formulations. Enbipu (chemical name: butylphthalide) is one of the representatives of the research and development achievements of stone medicine new drugs. It is the third national first class new drug with independent intellectual property rights in China, and also a global leading drug in the field of stroke treatment. Since its launch, it has cured or alleviated disease distress for over 10 million stroke patients. At the same time, Shiyao also has multiple new drug products such as Xuanning, Oulaining, Jinyouli, Duomeisu, Norinin, and Ke Aili. The successful launch and rapid growth of these new drugs have propelled the product structure of Shiyao to achieve a magnificent transformation from general medicine management to innovative medicine management. Abidol hydrochloride is one of the antiviral drugs developed and produced by Shiyao Group. During the recent prevention and control of the novel coronavirus epidemic, the team of Li Lanjuan, an academician of the CAE Member and a member of the high-level expert group of the National Health Commission, confirmed that Abidor can effectively inhibit novel coronavirus. Since mid January, Shiyao Group has donated over 26 million yuan worth of drugs and supplies, including Abidor, to Wuhan and key epidemic areas. Leading Chinese pharmaceutical companies to go global is one of the development visions of Shiyao Group. At present, stone medicine has nine innovative drugs for clinical trials in the United States, and butylphthalide soft capsules have been in the phase II clinical stage. Five products, including butylphthalide, antibody drug conjugate ADC (DP303c), and humanized gap junction protein 43 monoclonal antibody (ALMB-0166), have been certified as orphan drugs by the U.S. FDA and clinical trials of new drugs have been carried out. 19 varieties, including metformin hydrochloride tablets, have been approved by ANDA and sold in the United States. In addition, the hypertension treatment drug levo amlodipine maleate of Shijiazhuang Pharmaceutical Group passed the US Food and Drug Administration (FDA) new drug marketing review, becoming the first new drug fully approved by the FDA for Chinese pharmaceutical enterprises. Shiyao Group has established a comprehensive four level quality management system, and all drug production lines have passed the new version of GMP certification. At present, Shiyao has obtained a total of 12 CEP certificates and 35 DMF registration numbers, and 25 products have successfully passed on-site inspections by the US FDA. Undertaking social responsibility is an important manifestation of the values of Shiyao Group. For many years, Shiyao people have actively participated in public welfare undertakings. In various events such as SARS, Indonesia tsunami, Wenchuan earthquake, Yushu earthquake, Tanggu explosion, and medical treatment for severely ill children, Shiyao people have always actively extended a helping hand. The Hebei Shiyao Puen Charity Foundation, the main platform of Shiyao Group engaged in public welfare undertakings, actively carries out activities in the fields of aiding the sick, poor, impoverished, and elderly, as well as supporting education, continuously giving back to society through practical actions. Since its establishment, Shiyao Group has invested nearly 200 million yuan in public welfare undertakings. Looking ahead, Shiyao Group will continue to strengthen innovation, making it a globally influential and highly respected innovative pharmaceutical enterprise. Contribute to society with more, newer, and better medicines, and stride forward on the path of continuously leading innovation and forging excellent stone medicine! 2、 The proposed introduction of expert talent demand projects requires the introduction of anti-tumor, psychiatric, cardiovascular, metabolic fields, small molecule, cell therapy engineering, interfering nucleic acid drugs, international patents, macromolecular innovative drug projects, and new formulations (such as inhalers) projects.